Bayer has agreed to acquire South San Francisco-based Perfuse Therapeutics, Inc. for a total potential consideration of up to USD 2.45 billion, comprising a USD 300 million upfront payment and additional development, regulatory, and commercial milestone payments contingent on defined success criteria. The acquisition gives Germany-based Bayer AG (XTRA: BAYN) full global rights to PER-001, a small molecule endothelin receptor antagonist in Phase II development for glaucoma and diabetic retinopathy, extending Bayer's existing ophthalmology portfolio into a mechanism class with no currently approved agents targeting the endothelin pathway in either indication.
The transaction is structured as a full acquisition of Perfuse Therapeutics, with Bayer assuming complete ownership of the company and all associated intellectual property upon close. The USD 300 million upfront payment represents the guaranteed component, with the remaining potential value of approximately USD 2.15 billion contingent on the achievement of development, regulatory, and commercial milestones. Individual milestone thresholds and per-event payment values were not disclosed in the press release. Closing is subject to antitrust clearance and Perfuse stockholder approval.
PER-001: Mechanism and clinical stage
PER-001 is a bio-erodible intravitreal implant that delivers sustained-release endothelin receptor antagonism directly to the vitreous cavity via a single-use 25-gauge applicator. Endothelin functions as a potent vasoconstrictor and is upregulated across multiple ocular pathologies including glaucoma, diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. By blocking endothelin receptors expressed on retinal vascular and neuroretinal cells, PER-001 targets both the vascular and neurodegenerative components of ischemia-induced ocular disease. In glaucoma, the program is being evaluated for its capacity to improve visual field outcomes through a neuroprotective mechanism that operates independently of intraocular pressure reduction — a differentiation from the current standard of care, which is concentrated on pressure-lowering agents and does not address disease progression at the level of retinal ganglion cell loss. In diabetic retinopathy, the asset targets contrast sensitivity improvement and ischemia reduction. The Phase II trial for PER-001 is ongoing across both indications, with Perfuse Therapeutics having established R&D operations in Durham, North Carolina alongside its South San Francisco headquarters.
Competitive context
Other recent ophthalmology pipeline expansion deals include Merck's acquisition of EyeBio for approximately USD 3 billion — structured as USD 1.3 billion upfront plus up to USD 1.7 billion in milestones — targeted Restoret, a Wnt pathway agonist antibody in late-phase development for diabetic macular edema and wet AMD, indications that overlap with the diabetic retinopathy patient population addressed by PER-001.